Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 194,924 shares, a growth of 46.7% from the March 15th total of 132,839 shares. Currently, 2.2% of the company’s shares are sold short. Based on an average daily trading volume, of 1,025,160 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Ensysce Biosciences

Several large investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. boosted its position in shares of Ensysce Biosciences by 100.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after acquiring an additional 75,000 shares during the last quarter. DRW Securities LLC boosted its position in shares of Ensysce Biosciences by 42.4% during the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after acquiring an additional 29,336 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Ensysce Biosciences during the 3rd quarter valued at about $34,000. Virtu Financial LLC bought a new stake in shares of Ensysce Biosciences during the 3rd quarter valued at about $34,000. Finally, TRU Independence Asset Management 2 LLC bought a new stake in shares of Ensysce Biosciences during the 3rd quarter valued at about $25,000. Hedge funds and other institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Stock Down 4.9%

NASDAQ:ENSC traded down $0.03 during trading hours on Thursday, hitting $0.51. 161,631 shares of the company traded hands, compared to its average volume of 5,217,847. The firm’s 50-day simple moving average is $0.50 and its 200-day simple moving average is $1.21. Ensysce Biosciences has a one year low of $0.31 and a one year high of $4.85. The company has a market cap of $4.72 million, a PE ratio of -0.12 and a beta of 1.12.

Ensysce Biosciences (NASDAQ:ENSC) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.51. Ensysce Biosciences had a negative return on equity of 426.62% and a negative net margin of 200.87%.The business had revenue of $1.88 million for the quarter, compared to analysts’ expectations of $0.50 million. As a group, equities research analysts expect that Ensysce Biosciences will post -8.33 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.